DexCom Inc Stock Research

Market Summary

USD114.56+0.84

Market Closed

0.74%

DXCM Alerts

6 major insider sales recently.
Big jump in Earnings (Y/Y)

DXCM Stock Price

DXCM RSI Chart

DXCM Valuation

Market Cap

44.3B

Price/Earnings (Trailing)

129.7

Price/Sales (Trailing)

15.21

EV/EBITDA

77.15

Price/Free Cashflow

145.24

DXCM Price/Sales (Trailing)

DXCM Profitability

EBT Margin

13.43%

Return on Equity

16.01%

Return on Assets

6.33%

Free Cashflow Yield

0.69%

DXCM Fundamentals

DXCM Revenue

Revenue (TTM)

2.9B

Revenue Y/Y

16.76%

Revenue Q/Q

5.93%

DXCM Earnings

Earnings (TTM)

341.2M

Earnings Y/Y

1.8K%

Earnings Q/Q

-9.29%

Price Action

52 Week Range

66.89134.76

(Low)(High)

Last 7 days

0.9%

Last 30 days

-3.9%

Last 90 days

-2.2%

Trailing 12 Months

9.3%

DXCM Financial Health

Current Ratio

1.99

DXCM Investor Care

Buy Backs (1Y)

0.44%

Diluted EPS (TTM)

0.82

Peers (Alternatives to DexCom)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
SYK	104.1B	18.4B	2.26%	8.00%	44.16	5.64	7.84%	18.25%
ISRG	84.2B	6.2B	-4.47%	-13.27%	63.66	13.53	8.97%	-22.43%
BSX	69.1B	12.7B	0.59%	12.45%	99.06	5.45	6.68%	-32.95%
BDX	67.4B	19.0B	-5.16%	-6.78%	41.86	3.55	-0.43%	-8.78%
EW	49.8B	5.4B	2.41%	-25.12%	32.74	9.26	2.86%	1.25%
MID-CAP
SWAV	7.2T	489.7M	9.34%	31.15%	82.2K	16.8K	106.51%	2464.23%
PEN	10.2B	847.1M	-3.64%	34.52%	-5.1K	12.05	13.32%	-137.89%
GMED	5.2B	1.0B	-11.64%	-20.31%	30.19	5.09	6.76%	24.45%
IRTC	3.5B	410.9M	4.51%	-3.13%	-29.82	8.43	27.29%	-14.60%
TNDM	2.7B	801.2M	1.13%	-58.87%	-28.25	3.34	14.00%	-707.69%
SMALL-CAP
SILK	1.7B	138.6M	-15.68%	29.18%	-30.43	12.07	36.62%	-10.44%
ATEC	1.6B	350.9M	10.38%	49.06%	-10.84	4.7	44.26%	-5.42%
AVNS	1.3B	820.0M	-8.35%	-12.22%	25.89	1.59	10.13%	701.59%
CSII	828.4M	239.8M	0.30%	1.49%	-21.88	3.45	-4.74%	-31.15%

Financials for DexCom

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	4.2%	2,910	2,793	2,673	2,572	2,449
Gross Profit	3.8%	1,883	1,814	1,767	1,735	1,681
Operating Expenses	-3.6%	1,492	1,548	1,530	1,474	1,415
S&GA Expenses	6.6%	1,000	938	902	840	807
R&D Expenses	-6.5%	484	518	536	544	517
EBITDA	30.2%	565	434	385	366	-
EBITDA Margin	24.9%	0.19*	0.16*	0.14*	0.14*	-
Earnings Before Taxes	48.0%	391	264	230	252	257
EBT Margin	42.1%	0.13*	0.09*	0.05*	0.07*	-
Interest Expenses	0%	19.00	19.00	19.00	19.00	19.00
Net Income	39.8%	341	244	230	258	217
Net Income Margin	34.2%	0.12*	0.09*	0.06*	0.09*	-
Free Cahsflow	16.6%	305	261	216	95.00	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	10.1%	5,392	4,899	5,217	5,057	4,933
Current Assets	8.0%	3,669	3,399	3,809	3,747	3,684
Cash Equivalents	-8.0%	642	698	735	716	1,053
Inventory	-1.4%	307	311	340	342	357
Net PPE	6.3%	1,003	943	857	802	-
Goodwill	4.0%	26.00	25.00	26.00	27.00	27.00
Liabilities	6.0%	3,260	3,075	2,962	2,868	2,891
Current Liabilities	104.3%	1,839	901	807	711	721
Shareholder's Equity	16.8%	2,132	1,825	2,256	2,189	2,042
Retained Earnings	23.7%	480	388	287	236	139
Additional Paid-In Capital	9.0%	2,258	2,072	2,029	1,997	2,109
Shares Outstanding	0.0%	386	386	393	392	388

* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	4.2%	670	643	597	486	443
Share Based Compensation	6.5%	127	119	116	115	113
Cashflow From Investing	36.7%	-521	-823	-1,023	-515	-216
Cashflow From Financing	0.0%	-552	-552	11.00	15.00	10.00
Buy Backs	Infinity%	558	0.00	0.00	-	-

Risks for DXCM

What is the probability of a big loss on DXCM?

94.2%

Probability that DexCom stock will be more than 20% underwater in next one year

32.7%

Probability that DexCom stock will be more than 30% underwater in next one year.

29.6%

Probability that DexCom stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does DXCM drawdown profile look like?

Y-axis is the maximum loss one would have experienced if DexCom was unfortunately bought at previous high price.

Drawdowns

Returns for DXCM

Cumulative Returns on DXCM

39.5%

10-Year Cumulative Returns

33.5%

7-Year Cumulative Returns

47.3%

5-Year Cumulative Returns

23.1%

3-Year Cumulative Returns

What are the long-term rolling returns for DXCM?

FIve years rolling returns for DexCom.

Annualized Returns

Which funds bought or sold DXCM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-15	B. Riley Wealth Advisors, Inc.	added	54.5	348,701	762,701	0.02%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	reduced	-18.85	13,905,700	112,600,000	0.12%
2023-03-10	BAILLIE GIFFORD & CO	reduced	-4.43	501,188,000	1,959,380,000	2.04%
2023-03-08	Capital Asset Advisory Services LLC	new	-	206,210	206,210	0.02%
2023-03-06	Rockefeller Capital Management L.P.	added	1.45	4,034,000	13,495,000	0.07%
2023-03-02	LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA	new	-	225,121	225,121	-%
2023-02-28	Voya Investment Management LLC	reduced	-15.21	18,713,000	427,682,000	0.60%
2023-02-28	Orin Green Financial, LLC	unchanged	-	148,563	514,563	0.30%
2023-02-27	Parallax Volatility Advisers, L.P.	reduced	-99.77	-2,063,210	6,794	-%
2023-02-24	NATIXIS	added	0.97	1,930,330	6,743,330	0.04%

Latest Funds Activity

Are funds buying DXCM calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own DXCM

No. of Funds

DexCom News

Schedule 13G FIlings of DexCom

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 10, 2023	blackrock inc.	8.7%	33,535,680	SC 13G/A
Feb 09, 2023	vanguard group inc	11.34%	43,819,836	SC 13G/A
Jan 27, 2023	blackrock inc.	8.7%	33,882,680	SC 13G/A
Jan 25, 2023	blackrock inc.	8.8%	33,882,680	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 09, 2022	vanguard group inc	10.74%	10,410,319	SC 13G/A
Feb 08, 2022	blackrock inc.	8.4%	8,128,454	SC 13G/A
Dec 06, 2021	baillie gifford & co	4.85%	4,700,380	SC 13G/A
Feb 16, 2021	price t rowe associates inc /md/	2.2%	2,139,304	SC 13G/A
Feb 10, 2021	vanguard group inc	10.66%	10,232,245	SC 13G/A

DXCM Fair Value

DexCom fair value in different scenarios

The table shows the Fair Value estimates for DexCom for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	28.52 -75.10%	36.46 -68.17%	66.99 -41.52%	109.59 -4.34%	133.44 16.48%
Current Inflation	26.07 -77.24%	32.84 -71.33%	58.89 -48.59%	94.82 -17.23%	114.78 0.19%
Very High Inflation	23.05 -79.88%	28.46 -75.16%	49.35 -56.92%	77.71 -32.17%	93.30 -18.56%

Historical DexCom Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of DexCom

View All Filings

Date Filed	Form Type	Document
Mar 15, 2023	4	Insider Trading
Mar 14, 2023	4	Insider Trading
Mar 14, 2023	4	Insider Trading
Mar 14, 2023	4	Insider Trading
Mar 14, 2023	4	Insider Trading
Mar 14, 2023	4	Insider Trading
Mar 14, 2023	4	Insider Trading
Mar 14, 2023	4	Insider Trading
Mar 14, 2023	4	Insider Trading
Mar 14, 2023	4	Insider Trading

Latest Insider Trading transactions for DXCM

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-14	Stern Sadie	sold	-43,961	111	-393	evp chief human resources offi
2023-03-13	Regan Barry J.	sold	-213,603	106	-2,010	evp operations
2023-03-13	Flynn Paul R	sold	-295,643	106	-2,782	evp global revenue
2023-03-13	Dolan Matthew Vincent	sold	-661,956	106	-6,229	svp corporate strategy-develop
2023-03-10	Stern Sadie	back to issuer	-681,205	111	-6,115	evp chief human resources offi
2023-03-10	Pacelli Steven Robert	back to issuer	-1,299,910	111	-11,669	evp managing director dexcom v
2023-03-10	Leach Jacob Steven	back to issuer	-1,794,530	111	-16,109	evp chief technology officer
2023-03-10	Abbey Donald	back to issuer	-1,299,910	111	-11,669	evp global business services i
2023-03-10	Regan Barry J.	back to issuer	-632,746	111	-5,680	evp operations
2023-03-10	Selvaraj Shelly Ramasamy	back to issuer	-720,974	111	-6,472	svp chief information officer

About DexCom

Kevin R. Sayer

www.dexcom.com

6300

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DXCM Income Statement

2022-09-30

Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions

3 Months Ended

9 Months Ended

Sep. 30, 2022

Sep. 30, 2021

^[1]

Sep. 30, 2022

Sep. 30, 2021

^[1]

Income Statement [Abstract]

Revenue

$ 769.6

$ 650.2

$ 2,094.6

$ 1,750.3

Cost of sales

275.4

203.3

752.8

542.4

Gross profit

494.2

446.9

1,341.8

1,207.9

Operating expenses:

Research and development

110.3

128.8

367.9

367.3

Amortization of intangible assets

1.8

1.3

5.7

2.3

Selling, general and administrative

234.6

198.5

702.4

573.1

Total operating expenses

346.7

328.6

1,076.0

942.7

Operating income

147.5

118.3

265.8

265.2

Interest expense

(4.6)

(13.9)

(14.1)

Income from equity investments

0.0

0.2

0.0

Interest and other income (expense), net

3.3

(1.7)

5.5

(0.7)

Income before income taxes

146.2

112.0

257.6

250.4

Income tax expense

45.0

24.7

8.2

28.2

Net income

$ 101.2

$ 87.3

^[2]

$ 249.4

$ 222.2

^[3]

Basic net income per share (USD per share)

$ 0.26

$ 0.23

$ 0.64

$ 0.57

Shares used to compute basic net income per share (shares)

389.8

387.4

390.4

386.5

Diluted net income per share (USD per share)

$ 0.24

$ 0.21

$ 0.60

$ 0.54

Shares used to compute diluted net income per share (shares)

425.8

430.3

428.0

427.9

[1]	* We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” for further information.
[2]	* We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” for further information.
[3]	* We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” for further information.

DXCM Balance Sheet

2022-09-30

Consolidated Balance Sheets - USD ($)
$ in Millions

Sep. 30, 2022

Dec. 31, 2021

^[1]

Current assets:

Cash and cash equivalents

$ 698.1

$ 1,052.6

Short-term marketable securities

1,673.8

1,678.6

Accounts receivable, net

564.1

514.3

Inventory

311.0

357.3

Prepaid and other current assets

151.5

81.6

Total current assets

3,398.5

3,684.4

Property and equipment, net

1,002.5

801.8

Operating lease right-of-use assets

73.1

88.1

Goodwill

24.7

26.5

Intangibles, net

24.4

31.5

Deferred tax assets

342.3

290.5

Other assets

33.7

10.5

Total assets

4,899.2

4,933.3

Current liabilities:

Accounts payable and accrued liabilities

764.2

573.0

Accrued payroll and related expenses

112.7

125.2

Short-term operating lease liabilities

20.9

20.5

Deferred revenue

2.7

2.1

Total current liabilities

900.5

720.8

Long-term senior convertible notes

1,968.8

1,981.8

Long-term operating lease liabilities

82.1

98.6

Other long-term liabilities

123.3

90.0

Total liabilities

3,074.7

2,891.2

Commitments and contingencies

Stockholders’ equity:

Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at September 30, 2022 and December 31, 2021

0.0

Common stock, $0.001 par value, 800.0 million shares authorized; 393.1 million and 386.2 million shares issued and outstanding, respectively, at September 30, 2022; and 391.4 million and 388.0 million shares issued and outstanding, respectively, at December 31, 2021

0.4

Additional paid-in capital

2,072.1

2,108.7

Accumulated other comprehensive income (loss)

(41.1)

0.5

Retained earnings

388.1

138.7

Treasury stock, at cost; 6.9 million shares at September 30, 2022 and 3.4 million shares at December 31, 2021

(595.0)

(206.2)

Total stockholders’ equity

1,824.5

2,042.1

Total liabilities and stockholders’ equity

$ 4,899.2

$ 4,933.3

[1]

* We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” for further information.